GlassScriptPhysician profile
Daniel Isaac Feldman
NPI 1912391327
$13,189.20
in general payments reported to CMS, 2019-2025
16 companies · $8,927 in 2025
The $8,927 reported for 2025 was more than what 89% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $656 · 2021: $1,030 · 2022: $1,174 · 2023: $646 · 2024: $757 · 2025: $8,927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,300 · Food and Beverage: $2,504 · Consulting Fee: $1,525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,300.00 |
| Food and Beverage | $2,504.19 |
| Consulting Fee | $1,525.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $9,116.38 | 2022-2025 | |
| Biohaven Pharmaceuticals, INC. | $935.24 | 2021 | |
| Abbvie INC. | $899.23 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $706.50 | 2022 | |
| Lundbeck LLC | $682.67 | 2021-2025 | Vyepti |
| Novartis Pharmaceuticals Corporation | $250.66 | 2019 | |
| Genentech USA, INC. | $110.20 | 2019 | |
| Acorda Therapeutics, INC | $98.40 | 2019 | |
| Axsome Therapeutics, INC. | $91.65 | 2025 | Symbravo |
| Lilly USA, LLC | $91.49 | 2019 | |
| Amgen INC. | $78.86 | 2019 | |
| Allergan, INC. | $59.76 | 2022 | |
| Janssen Biotech, INC. | $22.16 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.55 | 2024 | Keveyis |
| Portola Pharmaceuticals, LLC | $14.40 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $12.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Feldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.